3652 results for «231»
3652 results
Strategies to enhance bifurcation PCI outcomes
21 May 2026 – From EuroPCR 2026
This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...
Aortic stenosis: from diagnostic to treatment
21 May 2026 – From EuroPCR 2026
This session provides an in-depth review of contemporary management of aortic stenosis, covering diagnostic advancements, temporal trends, and treatment outcomes. It includes insights from the LAPLACE-TAVI registry focusing on low-risk patients, discusses the growing feasibility of day-case TAVI procedures, compares transcatheter and surgical valve replacements in...
Left main PCI, what is known and what is new
21 May 2026 – From EuroPCR 2026
This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...
INOCA/ANOCA: technical aspects
20 May 2026 – From EuroPCR 2026
This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...
FFR and non-hyperaemic pressure ratios
20 May 2026 – From EuroPCR 2026
This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.
Other right-sided and tricuspid valve interventions
20 May 2026 – From EuroPCR 2026
This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.
New frontiers in coronary disease treatment
21 May 2026 – From EuroPCR 2026
Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.
STEMI management around the world
21 May 2026 – From EuroPCR 2026
This session presents a global perspective on STEMI management, addressing strategies to reduce reperfusion delays through nurse-integrated pathways and comparing intracoronary versus intravenous Tirofiban use during primary PCI. It includes epidemiological insights from Rwanda and Egypt, evaluates thrombo-aspiration practices in Sub-Saharan Africa, and examines outcomes in...
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
